MPA withdraws Bend's Oregon plant GMP certificate citing deficiencies

By Gareth Macdonald contact

- Last updated on GMT

iStock/kaarsten
iStock/kaarsten

Related tags: Clinical trial

Swedish regulators have withdrawn a GMP certificate issued to Bend Research after deeming the firm’s plan to address deviations at its Oregon plant “partly unacceptable.”

The Medical Products Agency (MPA) outlined its concerns about the facility in a post on the EudraGMP database​, citing a number of deviations from good manufacturing practices (GMP) observed during an inspection in February.

The MPA cited “data integrity” as a critical deficiency. It also reported major deficiencies relating to validation, hygiene routines, identification of mobile equipment in the multipurpose facilities and documentation.

In addition, the agency expressed concern that deficiencies observed during inspections conducted in 2013 and August last year have not been corrected.

An MPA spokesman told us "Bend Research Inc has received an inspection report and responded to it with a plan for corrective and preventive actions.

"The response has been evaluated by the MPA and judged to be partly unacceptable. After this the statement of non-compliance with GMP has been issued. The document that was withdrawn was a previously expired GMP-certificate​.”

The MPA also recommended that clinical trial and marketing authorisation applications listing Bend as a manufacturer are not accepted until a new certificate has been issued.

Response

The Swedish regulator issued a GMP certificate for the Oregon facility – which is known as BRIM and makes oral solid dose products for clinical trials and commercial supply – in 2013​.

Later that Bend was acquired by Capsugel, which invested $20m in November 2013​ to add commercial spray drying capacity at the Oregon site.

A Capsugel spokesman told us: “We are working diligently to address the deficiencies identified during the MPA’s recent inspections at Bend Research. Per the MPA’s statement of May 16, 2016, no recall of batches has been deemed necessary to date. 

"We have initiated a series of Corrective and Preventive Actions, and have retained recognized third-party consultants to verify that our systems, processes, procedures and batch releases meet EU GMP standards.  We are confident that we can resolve this issue quickly so we can continue to support our customers’ ability to provide patients access to the high-quality drug products they need​."

According to the spokesman the facility "provides formulation development clinical and commercial manufacturing services for a wide range of dosage forms​."

Related topics: Markets & Regulations, QA/QC, Regulations

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us

Products

View more

Webinars